Trial Profile
A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Fixed Dose Study Comparing the Efficacy and Safety of GW597599/Paroxetine Combination or Paroxetine Monotherapy to Placebo in Patients With Social Anxiety Disorder (SAD)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Vestipitant (Primary) ; Paroxetine
- Indications Social phobia
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 15 Oct 2008 Actual start date changed from Oct 2004 to Nov 2004 as reported by ClinicalTrials.gov.
- 11 Jan 2008 Status changed from in progress to completed.
- 02 Mar 2007 New trial record.